SOL, DOGE and XRP prices are down more than 4% in the past 24 hours, data shows, with the broad-based CoinDesk (CD20) down more than 2%. The volatility follows a week of macro uncertainty ...

Rituximab is an anti-CD20 monoclonal antibody that is being used off-label for the treatment of pempiigus vulgaris. To date, 153 patients have been treated and reported in the literature.

Micrograph of a diffuse large B cell lymphoma, AbbVie and partner Genmab have FDA approval for the lead drug in their $3.9 billion cancer partnership, with bispecific antibody Epkinly now cleared ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

The following transcript is automatically generated and may contain typos or misspellings. Please listen to the episode for the most accurate language. Dr. Susan Manzi 0:00 Hello everyone. I'm Dr.

The 5-year relative survival rate for chronic lymphocytic leukemia (CLL) among adults ages 20 or older is 87%. Treatment can help people manage CLL symptoms and improve their overall outlook.

ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the ...

Table 1. Approved Therapies for Autoimmune Disease and Their Targets Autoimmune diseases represent a wide range of disorders affecting specific organs or the entire body, all characterised by the ...